Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4...
Private Wellness Club Continuum Unlocks Final Membership Tier at West Village Flagship